Last reviewed · How we verify
Selexipag for oral use
At a glance
| Generic name | Selexipag for oral use |
|---|---|
| Also known as | ACT-293987 |
| Sponsor | Actelion |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension (PHASE2)
- A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option (PHASE3)
- Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension (PHASE3)
- A Study of Selexipag in Healthy Male Participant (PHASE1)
- Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension. (PHASE4)
- Absolute Bioavailability of a Single Oral Dose of Selexipag in Healthy Subjects (PHASE1)
- A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag (PHASE2)
- Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Selexipag for oral use CI brief — competitive landscape report
- Selexipag for oral use updates RSS · CI watch RSS
- Actelion portfolio CI